Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Annamycin is a next-generation anthracycline, which is being evaluated in combination with cytarabine for the treatment of subjects with acute myeloid leukemia.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
Liposomal-Annamycin is a Topoisomerase II inhibitor small molecule drug which is currently being evaluated in phase 1/2 clinical trials in combination with Cytarabine for the treatment of Acute Myeloid Leukemia.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
AnnAraC (annamycin), is a next-generation anthracycline, topioisomerase II inhibitor, designed to avoid multidrug resistance mechanisms and to have little to no cardiotoxicity. It is being investigated for soft tissue sarcoma and AML.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: AnnAraC
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Ara-C (Annamycin) forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML and soft tissue sarcoma lung metastases.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Ara-C
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
AnnAraC (annamycin), is a next-generation anthracycline, topioisomerase II inhibitor, designed to avoid multidrug resistance mechanisms and to have little to no cardiotoxicity. It is being investigated for soft tissue sarcoma.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: AnnAraC
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Annamycin forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML and soft tissue sarcoma lung metastases..
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2023
Details:
Annamycin, is a next-generation anthracycline, topioisomerase II inhibitor, designed to avoid multidrug resistance mechanisms and to have little to no cardiotoxicity. It is being investigated for soft tissue sarcoma.
Lead Product(s): L-Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Annamycin forms complexes with DNA by intercalation between base pairs and inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex. It is being developed in combination with cytarabine for AML.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2023
Details:
Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells.
Lead Product(s): WP1122
Therapeutic Area: Oncology Product Name: WP1122
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022